Bilimsel çalışmalar

Prof. Dr. Bülent Karabulut

196 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön
  1. Use of docetaxel in combination with octreotide as a synergistic combination for prostate cancer with apoptotic and antiangiogenic effects.

    Journal of Clinical Oncology, 2014

    DOI 10.1200/jco.2014.32.15_suppl.e13515 Kaynak: OpenAlex

  2. Complications and Toxicities After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

    Annals of Surgical Oncology, 2013

    DOI 10.1245/s10434-012-2853-x PMID 23456387 66 atıf (OpenAlex) Kaynak: OpenAlex

  3. Examining the Effect of the Case Management Model on Patient Results in the Palliative Care of Patients With Cancer

    American Journal of Hospice and Palliative Medicine®, 2013

    DOI 10.1177/1049909113506980 PMID 24097840 26 atıf (OpenAlex) Kaynak: OpenAlex

  4. Evaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer.

    PubMed, 2013

    PMID 23818348 9 atıf (OpenAlex) Kaynak: OpenAlex

  5. A multi-institutional evaluation of carboplatin plus docetaxel regimen in elderly patients with advanced gastric cancer.

    PubMed, 2013

    PMID 23613400 3 atıf (OpenAlex) Kaynak: OpenAlex

  6. Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer

    Molecular and Clinical Oncology, 2013

    DOI 10.3892/mco.2013.212 PMID 24649328 3 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  7. Survival analysis of metastatic colorectal cancer patients who were treated with the five major therapeutic agents over the course of disease.

    PubMed, 2013

    PMID 24065478 1 atıf (OpenAlex) Kaynak: OpenAlex

  8. Paclitaxel in combination with AT-101 induces apoptosis via supressing Bcl-2, bcl-XL, mcl-1 proteins in human breast cancer cells.

    Journal of Clinical Oncology, 2013

    DOI 10.1200/jco.2013.31.15_suppl.e13578 1 atıf (OpenAlex) Kaynak: OpenAlex

  9. Üçlü-Negatif Meme Kanserli Hastalarda Güncel Klinik Uygulamalar ve Devam Eden Klinik Çalışmalar

    Turkiye Klinikleri General Surgery - Special Topics, 2013

    Kaynak: OpenAlex

  10. Kolorektal Kanser Tedavisinde Hedefe Yönelik Ajanlar ve Uygulama Alanları

    Turkiye Klinikleri Medical Oncology - Special Topics, 2013

    Kaynak: OpenAlex

  11. Metastatik Küçük Hücreli Dışı Akciğer Kanserinde İdame Tedavinin Yeri

    Turkiye Klinikleri Medical Oncology - Special Topics, 2013

    Kaynak: OpenAlex

  12. Comparison of Survival of Colorectal Cancer Patients Undergone for Metastasectomy Before or After Chemotherapy with Liver Only Metastases

    Annals of Oncology, 2013

    DOI 10.1093/annonc/mdt203.225 Açık erişimli tam metinKaynak: OpenAlex

  13. Interpreting Genomic Diversity for Breast Cancer: Molecular Subtypes of Breast Cancer in Very Young Women (≤35 Y) in Western Turkey

    Annals of Oncology, 2013

    DOI 10.1093/annonc/mdt078.5 Açık erişimli tam metinKaynak: OpenAlex

  14. Do Tumour Characteristics and Disease Localization Predict Bevacizumab Activity in the Treatment of Metastatic Colorectal Cancer?

    Annals of Oncology, 2013

    DOI 10.1093/annonc/mdt203.196 Açık erişimli tam metinKaynak: OpenAlex

  15. Fluorouracil and folinic acid bolus schedule (nordic regimen) combined with irinotecan as a first-line chemotherapy in metastatic colorectal cancer

    DergiPark (Istanbul University), 2013

    Kaynak: OpenAlex

  16. Capecitabine maintenance therapy after docetaxel/capecitabine combination chemotherapy in patients with metastatic breast cancer.

    Journal of Clinical Oncology, 2013

    DOI 10.1200/jco.2013.31.15_suppl.e12018 Kaynak: OpenAlex

  17. Understanding international genomic diversity for breast cancer: Comparison of molecular subtypes of breast cancer in very young women (age ≤ 35) between Izmir (Western Turkey) and Boston (Massachusetts, USA).

    Journal of Clinical Oncology, 2013

    DOI 10.1200/jco.2013.31.15_suppl.e12509 Kaynak: OpenAlex

  18. Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells

    Molecular Biology Reports, 2012

    DOI 10.1007/s11033-012-2469-z PMID 23269627 42 atıf (OpenAlex) Kaynak: OpenAlex

  19. Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels

    Journal of Cancer Research and Clinical Oncology, 2012

    DOI 10.1007/s00432-012-1187-1 PMID 22411600 23 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  20. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone‐refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A

    British Journal of Urology, 2012

    DOI 10.1111/j.1464-410x.2012.11392.x PMID 22882676 16 atıf (OpenAlex) Kaynak: OpenAlex

  21. The Frequency and Significance of Radiologically Detected Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer

    Medical Principles and Practice, 2012

    DOI 10.1159/000337426 PMID 22572176 17 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  22. Comparing Time to Disease Progression of Irinotecan and Oxaliplatin-based Chemotherapies in Colorectal Cancer Patients With Liver Only Metastasis

    American Journal of Clinical Oncology, 2012

    DOI 10.1097/coc.0b013e318248da7c PMID 22643568 6 atıf (OpenAlex) Kaynak: OpenAlex

  23. 98P Octreotide in Combination with Docetaxel Triggers Apoptosis by Inducing Sstr2 and Sstr5 Levels in Human Breast Cancer Cells, Mcf-7 and Mda-Mb-231

    Annals of Oncology, 2012

    DOI 10.1016/s0923-7534(19)65742-x 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  24. 52 Examining the Effect of the Case Management Model on Patient Results in the Palliative Care of Cancer Patients

    European Journal of Oncology Nursing, 2012

    DOI 10.1016/s1462-3889(12)70067-4 1 atıf (OpenAlex) Kaynak: OpenAlex

  25. 99P Zoledronic Acid in Combination with Serine/Threonine Phosphatase Inhibitors Induces Cytotoxicity and Apoptosis in Human Breast Cancer Cells via Decreasing the Activities of Pp1 and Pp2A

    Annals of Oncology, 2012

    DOI 10.1016/s0923-7534(19)65743-1 Açık erişimli tam metinKaynak: OpenAlex

  26. 94P Comparison of A Novel, Label-Free, and Real-Time cell Based System (Xcelligence) With a Conventional Viability Assay (Xtt) to Determine the Anti-Proliferative Effect of At-101 in Human Breast Cancer Cells

    Annals of Oncology, 2012

    DOI 10.1016/s0923-7534(19)65737-6 Açık erişimli tam metinKaynak: OpenAlex

  27. Front & Back Matter

    Medical Principles and Practice, 2012

    DOI 10.1159/000342183 Açık erişimli tam metinKaynak: OpenAlex

  28. p53 Protein Accumulation and Presence of Visceral Metastasis Are Independent Prognostic Factors for Survival in Patients with Metastatic Inflammatory Breast Carcinoma

    Medical Principles and Practice, 2011

    DOI 10.1159/000319916 PMID 21252573 5 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  29. Targeting Bcl-2 Protein to Enhance Chemosensitivity of Hormone Refractory Prostate Cancer Cell Line, DU-145 by a Synergistic Combination of Docetaxel and Gossypol

    Turkiye Klinikleri Journal of Medical Sciences, 2011

    DOI 10.5336/medsci.2010-19849 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  30. Kolon Kanserinin Farmakogenetiği

    Turkiye Klinikleri Medical Oncology - Special Topics, 2011

    Kaynak: OpenAlex

  31. Liposomal Doxorubicin-Related Palmar-Plantar Erthrodysesthesia (Hand-And Foot Syndrome): Report Of A Case

    Journal of Turkish Society of Obstetric and Gynecology, 2011

    DOI 10.5505/tjod.2011.87059 Açık erişimli tam metinKaynak: OpenAlex

  32. Zoledronik asit in protein fosfataz inhibitörleri ile kombinasyonunun insan hormon refrakter prostat kanser kanseri hücrelerinde farnesilprofosfat sentaz üzerine etkilerinin araştırılması

    Çanakkale Onsekiz Mart University AVESIS, 2011

    Kaynak: OpenAlex

  33. Prostat kanseri hücre hatlarında zoledronik asit uygulamasının sitotoksik ve anti anjiogenik etkilerinin araştırılması

    Çanakkale Onsekiz Mart University AVESIS, 2011

    Kaynak: OpenAlex

  34. Comparison of XTT and Alamar blue assays in the assessment of the viability of various human cancer cell lines by AT-101 (−/− gossypol)

    Toxicology Mechanisms and Methods, 2010

    DOI 10.3109/15376516.2010.508080 PMID 20843265 40 atıf (OpenAlex) Kaynak: OpenAlex

  35. Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines

    Molecular Biology Reports, 2010

    DOI 10.1007/s11033-010-0102-6 PMID 20349282 19 atıf (OpenAlex) Kaynak: OpenAlex

  36. Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer

    Journal of Experimental & Clinical Cancer Research, 2010

    DOI 10.1186/1756-9966-29-102 PMID 20673323 22 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  37. Palliative Care Activity in the field of Oncology in Turkey

    Journal of Palliative Care, 2010

    DOI 10.1177/082585971002600408 PMID 21268524 13 atıf (OpenAlex) Kaynak: OpenAlex

  38. Radiosensitization of hormone-refractory prostate cancer cells by gossypol treatment.

    PubMed, 2010

    PMID 21229643 9 atıf (OpenAlex) Kaynak: OpenAlex

  39. Apoptosis-Mediated Cytotoxic Effects of Ibandronic Acid on Hormone- and Drug-Refractory Prostate Cancer Cells and Human Breast Cancer Cells

    Journal of International Medical Research, 2010

    DOI 10.1177/147323001003800511 PMID 21309480 2 atıf (OpenAlex) Kaynak: OpenAlex

  40. Bisphosphonate (Zoledronic Acid) Associated Adverse Events: Single Center Experience

    2010

    4 atıf (OpenAlex) Kaynak: OpenAlex

  41. PP291 TAC REGIMEN INDUCED METABOLIC SYNDROME-X IN BREAST CANCER PATIENTS

    Clinical Nutrition Supplements, 2010

    DOI 10.1016/s1744-1161(10)70366-5 Kaynak: OpenAlex

  42. İnsan meme kanseri hücre hatlarında AT 101 trail kombinasyonunun sitotoksik ve apoptotik etkilerinin araştırılması

    Çanakkale Onsekiz Mart University AVESIS, 2010

    Kaynak: OpenAlex

  43. Can hyperbaric oxygenation decrease doxorubicin hepatotoxicity and improve regeneration in the injured liver?

    Journal of Hepato-Biliary-Pancreatic Surgery, 2009

    DOI 10.1007/s00534-009-0059-9 PMID 19288285 2 atıf (Europe PMC) Kaynak: OpenAlex

  44. Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination

    Molecular Biology Reports, 2009

    DOI 10.1007/s11033-009-9501-y PMID 19288219 34 atıf (OpenAlex) Kaynak: OpenAlex

  45. Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells

    European Cytokine Network, 2009

    DOI 10.1684/ecn.2009.0159 PMID 19825521 26 atıf (OpenAlex) Kaynak: OpenAlex

  46. Regulation of growth factors in hormone‐ and drug‐resistant prostate cancer cells by synergistic combination of docetaxel and octreotide

    British Journal of Urology, 2009

    DOI 10.1111/j.1464-410x.2009.08340.x PMID 19191785 22 atıf (OpenAlex) Kaynak: OpenAlex

  47. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer

    Medical Oncology, 2009

    DOI 10.1007/s12032-009-9253-5 PMID 19526201 15 atıf (OpenAlex) Kaynak: OpenAlex

  48. The effect of racemic gossypol and at-101 on angiogenic profile of ovcar-3 cells: a preliminary molecular framework for gossypol enantiomers.

    PubMed, 2009

    PMID 20010531 13 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  49. Enhancement of taxane-induced cytotoxicity and apoptosis by gossypol in human breast cancer cell line MCF-7.

    PubMed, 2009

    PMID 19810142 11 atıf (OpenAlex) Kaynak: OpenAlex

  50. Palliative radiotherapy for the skin metastasis of ovarian cancer: a case report and review of the literature

    Medical Oncology, 2009

    DOI 10.1007/s12032-009-9259-z PMID 19536657 12 atıf (OpenAlex) Kaynak: OpenAlex